Af­ter im­plod­ing three years ago, Aptinyx fol­lows a painful set­back with yet an­oth­er PhII fail­ure

More than three years af­ter Aptinyx shares $AP­TX were squashed by a mid-stage set­back for its lead drug, the biotech has un­veiled the bot­tom-line re­sults for a fol­low-up at­tempt to suc­ceed where it first failed bad­ly.

And it’s not pret­ty.

Pur­su­ing a 50 mg dose of NYX-2925 in a study of 229 pa­tients with ad­vanced painful di­a­bet­ic pe­riph­er­al neu­ropa­thy — where re­searchers found some cause for en­cour­age­ment in 2019 — did noth­ing to move the di­al in com­par­i­son to a place­bo. The biotech not­ed:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER